Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09RZH
|
|||
| Former ID |
DIB000134
|
|||
| Drug Name |
AdRTVP-1
|
|||
| Synonyms |
AdRTVP-1, Baylor College of Medicine; Gene therapy (RTVP-1); Gene therapy (RTVP-1), Baylor College of Medicine; Related to Testes-Specific Vespid and Pathogenesis Protein-1 adenoviral gene therapy, BCM
Click to Show/Hide
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 1 | [1] | |
| Company |
Baylor College of Medicine
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glioma pathogenesis-related protein 1 (GLIPR1) | Target Info | Modulator | [1] |
| Reactome | PPARA activates gene expression | |||
| WikiPathways | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 2006 Jul;13(7):658-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.